Nuwellis Study Validates Epoprostenol as Alternative Anticoagulant for Pediatric Aquadex Therapy
Event summary
- Nuwellis' study published in Frontiers in Pediatrics demonstrates epoprostenol as a safe alternative anticoagulant for pediatric Aquadex therapy.
- The single-center retrospective study reviewed 46 children (52 treatment courses) treated between September 2022 and September 2025.
- Epoprostenol maintained filtering circuits without increasing bleeding risk or need for blood-pressure support.
- Nuwellis provided modest financial support for open-access publication but did not fund the research itself.
The big picture
This study strengthens Nuwellis' position in pediatric critical care by providing an alternative anticoagulation strategy, addressing a key challenge in managing fluid overload in critically ill children. The findings could expand the adoption of Aquadex therapy among physicians treating complex pediatric patients who are not candidates for conventional therapies.
What we're watching
- Clinical Adoption
- How quickly pediatric critical care units will adopt epoprostenol as an alternative anticoagulant for Aquadex therapy.
- Regulatory Pathways
- Whether Nuwellis seeks expanded indications or additional clinical validation for broader use of this strategy.
- Competitive Positioning
- The pace at which competitors develop similar anticoagulation strategies for ultrafiltration therapies.